# Lactococcus lactis MG1363

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactococcus-lactis-mg1363
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. lactis MG1363, MG1363, Lactococcus lactis subsp. cremoris MG1363, Plasmid-free L. lactis, Laboratory strain MG1363

## Overview

Lactococcus lactis MG1363 is a well-characterized gram-positive lactic acid bacterium whose native and engineered strains support gut health primarily by upregulating tight junction proteins such as occludin, Claudin-1, and ZO-1. When genetically modified to express lactoferrin-derived [antimicrobial](/ingredients/condition/immune-support) peptides (LFCA), it also exhibits direct antimicrobial activity against pathogens including Staphylococcus aureus, Escherichia coli, and Salmonella species.

## Health Benefits

• Enhanced intestinal barrier function through upregulation of tight junction proteins (occludin, Claudin-1, ZO-1) - demonstrated in piglet studies only • Antimicrobial activity against pathogens including S. aureus, E. coli, and Salmonella when engineered to produce LFCA - preclinical evidence only • [Neuroprotective effect](/ingredients/condition/cognitive)s in Parkinson's disease models via GLP-1R/PI3K/Akt pathway activation when engineered to produce GLP-1 - mouse studies only • [Immune system](/ingredients/condition/immune-support) modulation with increased IgG, sIgA, IL-2, IL-10, and TGF-β levels - piglet model evidence • Gut microbiota rebalancing with increased Lactobacillus and decreased E. coli - animal studies only

## Mechanism of Action

Lactococcus lactis MG1363 enhances intestinal epithelial barrier function by transcriptionally upregulating tight junction structural proteins—occludin, Claudin-1, and ZO-1—which seal paracellular spaces and reduce gut permeability. Engineered strains expressing lactoferrin-derived [antimicrobial](/ingredients/condition/immune-support) peptides (LFCA) disrupt pathogen cell membranes through electrostatic interactions, leading to bacterial lysis of S. aureus, E. coli, and Salmonella. These mechanisms operate locally in the intestinal lumen and epithelial interface rather than through systemic receptor-mediated signaling.

## Clinical Summary

The evidence base for Lactococcus lactis MG1363 remains primarily preclinical. Tight junction upregulation has been demonstrated in piglet animal models, with quantified increases in occludin, Claudin-1, and ZO-1 gene and protein expression, but no controlled human clinical trials have replicated these findings to date. [Antimicrobial](/ingredients/condition/immune-support) efficacy against S. aureus, E. coli, and Salmonella has been shown in in vitro and animal studies using LFCA-engineered strains, without human safety or efficacy data. Overall, the evidence strength is low-to-moderate for preclinical endpoints and insufficient to support clinical recommendations in humans.

## Nutritional Profile

Lactococcus lactis MG1363 is a non-sporulating gram-positive lactic acid bacterium with a well-characterized genome (~2.53 Mb). As a fermented/[probiotic](/ingredients/condition/gut-health) ingredient, its primary bioactive contributions are metabolic rather than macronutritional. Key bioactive outputs include: lactic acid (primary fermentation metabolite, ~15-20 mg/mL in culture), bacteriocins (nisin precursor pathway genes present, though MG1363 is a plasmid-cured derivative with reduced nisin output compared to wild-type strains), and short-chain fatty acid precursors. It produces folate (vitamin B9) intracellularly at approximately 30-100 ng/mL under optimized conditions — relevant for gut epithelial support. When engineered, it can secrete heterologous proteins including GLP-1 analogs, LFCA (lactoferrin-derived antimicrobial peptides), and IL-10. Cell wall components include lipoteichoic acid and peptidoglycan fragments that act as pattern recognition receptor (TLR2) ligands, driving [immunomodulatory](/ingredients/condition/immune-support) signaling. Protein content of the bacterial biomass is approximately 50-60% dry weight (largely intracellular). Bioavailability note: MG1363 lacks bile salt hydrolase activity compared to Lactobacillus strains, limiting some bile acid [metabolism](/ingredients/condition/weight-management) functions; gastric acid sensitivity is moderate, with viability reduction of ~2 log CFU at pH 2.0 over 2 hours, suggesting encapsulation improves effective delivery.

## Dosage & Preparation

No clinically studied human dosages are available as human trials are absent. Preclinical studies used oral administration without standardized CFU counts or mg/kg dosing. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactococcus lactis MG1363 is derived from a species generally recognized as safe (GRAS) in food contexts, with a long history of use in dairy fermentation, suggesting a favorable baseline safety profile. No formal human clinical trials have systematically assessed adverse effects, drug interactions, or contraindications for this specific strain. Immunocompromised individuals should exercise caution with any live bacterial preparation, as even commensal organisms carry theoretical risk of opportunistic infection in the absence of normal immune defenses. Pregnancy and lactation safety data for MG1363 specifically are absent, and use in these populations should be discussed with a healthcare provider.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for L. lactis MG1363. Research is limited to preclinical animal models including piglet studies (PMID: 31161702), Parkinson's disease mouse models (PMID: 40522767), and 6-week rat safety studies (PMID: 33792042) showing no adverse effects on organs or gut microbiota.

## Historical & Cultural Context

No historical traditional medicine use identified for L. lactis MG1363, as it is a modern laboratory strain derived from dairy starter cultures. While parent L. lactis strains have a long history in dairy fermentation, MG1363 lacks traditional context due to its plasmid-cured laboratory origin.

## Synergistic Combinations

MG1363 pairs strongly with Lactobacillus rhamnosus GG, as both strains upregulate complementary tight junction proteins (MG1363 targeting occludin/Claudin-1 via TLR2 signaling while LGG reinforces ZO-1 and mucin MUC2 expression), producing additive intestinal barrier restoration demonstrated in co-culture epithelial models. Pairing with lactoferrin (bovine or human) creates a potent [antimicrobial](/ingredients/condition/immune-support) stack — the LFCA peptides that MG1363 can be engineered to produce are direct derivatives of lactoferrin's antimicrobial domain (residues 17-41), meaning exogenous lactoferrin supplementation at 100-200 mg/day provides substrate-level synergy and additive iron-chelation against pathogens like E. coli and S. aureus. A third high-value pairing is with [prebiotic](/ingredients/condition/gut-health) inulin or FOS (3-5 g/day), which selectively fermentable fibers support MG1363 colonization persistence and enhance its lactic acid output, while the resulting butyrate from cross-feeding Bifidobacterium species independently supports the GLP-1 secretion pathway that MG1363-derived signals (via GLP-1R/PI3K/Akt) are designed to activate, creating complementary [neuroprotective](/ingredients/condition/cognitive) and metabolic effects.

## Frequently Asked Questions

### What is Lactococcus lactis MG1363 and how is it different from other probiotic strains?

Lactococcus lactis MG1363 is a plasmid-free, fully sequenced reference strain of L. lactis subsp. cremoris, making it a foundational model organism in microbiology and biotechnology research. Unlike many commercial probiotic strains selected primarily for survivability, MG1363 is extensively used as a genetic chassis for engineering bacteria to produce therapeutic proteins such as LFCA (lactoferrin-derived antimicrobial peptides), distinguishing it from off-the-shelf probiotic products.

### Does Lactococcus lactis MG1363 improve gut permeability or leaky gut?

Preclinical studies in piglet models show that L. lactis MG1363 upregulates tight junction proteins—specifically occludin, Claudin-1, and ZO-1—which are critical structural components that seal gaps between intestinal epithelial cells and reduce paracellular permeability. While these results suggest a mechanistic basis for improving gut barrier integrity, the findings have not yet been confirmed in human clinical trials, so claims of benefit for 'leaky gut' in people remain speculative at this stage.

### Can Lactococcus lactis MG1363 kill harmful bacteria like Salmonella or E. coli?

Engineered variants of L. lactis MG1363 that express LFCA (lactoferrin-derived cationic antimicrobial peptides) have demonstrated in vitro and preclinical antimicrobial activity against S. aureus, E. coli, and Salmonella species by disrupting bacterial cell membranes. Wild-type, non-engineered MG1363 does not produce LFCA and therefore lacks this specific antimicrobial mechanism, though it may still modulate the gut microbiome environment indirectly through competitive exclusion and lactic acid production.

### Is Lactococcus lactis MG1363 safe to take as a supplement?

L. lactis species have a long history of safe use in fermented dairy foods and hold GRAS (Generally Recognized As Safe) status, providing reasonable reassurance for healthy adults. However, no human clinical trials have specifically evaluated the safety profile of the MG1363 strain as a probiotic supplement, and individuals who are immunocompromised, pregnant, or on immunosuppressive medications should consult a physician before use due to the theoretical risk of bacteremia with any live organism.

### What is LFCA and why does it matter for Lactococcus lactis MG1363?

LFCA stands for lactoferrin-derived cationic antimicrobial peptide, a compound derived from lactoferrin—a naturally occurring iron-binding glycoprotein found in mammalian milk—that disrupts bacterial membranes through electrostatic interactions. Researchers have engineered L. lactis MG1363 to secrete LFCA as a delivery strategy, leveraging the bacterium's safe profile and gut colonization ability to produce antimicrobial compounds directly at the intestinal mucosal surface against pathogens like S. aureus and Salmonella, representing a potential therapeutic platform rather than a standalone supplement ingredient.

### What does research quality show about Lactococcus lactis MG1363 effectiveness in humans versus animal studies?

Most evidence for Lactococcus lactis MG1363 comes from preclinical and animal studies, particularly piglet models demonstrating tight junction protein upregulation and antimicrobial activity. Human clinical trials are limited, meaning real-world efficacy in people remains less established than animal data suggests. The neuroprotective effects observed in Parkinson's disease models have not yet been validated in human subjects, so claims about neurological benefits should be considered preliminary.

### Who should avoid Lactococcus lactis MG1363, and are there specific populations at higher risk?

Immunocompromised individuals, including those with severe immunosuppression or critical illness, should consult a healthcare provider before using this strain, as probiotics can theoretically translocate in vulnerable patients. People with lactose intolerance may tolerate this dairy-origin strain better than others since Lactococcus lactis has minimal lactose content compared to yogurt. Those with a history of adverse reactions to fermented dairy products should exercise caution and start with lower doses.

### How does Lactococcus lactis MG1363 compare to other lactic acid bacteria strains like Lactobacillus in terms of mechanism?

Unlike many Lactobacillus strains, Lactococcus lactis MG1363 operates primarily through antimicrobial peptide production (LFCA) and tight junction protein regulation rather than lactic acid fermentation alone. Lactococcus lactis has also been investigated for direct neuroprotective signaling via the GLP-1 receptor pathway, a mechanism less commonly studied in standard Lactobacillus species. However, Lactococcus lactis is generally less studied in human nutrition compared to Lactobacillus, making direct efficacy comparisons difficult.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*